Medigene(DE:MDG1)
€0.01-0.00 (-16.67%)
DE:MDG1
Medigene financials statements
€0.01
At close:-0.00 (-16.67%)
Medigene (MDG1) Ratios
7 Followers
Medigene Ratios
DE:MDG1's free cash flow for Q2 2024 was €-3.69M. For the 2024 fiscal year, DE:MDG1's free cash flow was decreased by €-151.00K and operating cash flow was €-3.54M. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.53 | 5.02 | 3.01 | 3.23 | 5.65 |
| Quick Ratio | 2.53 | 5.02 | 3.01 | 3.23 | 5.65 |
| Cash Ratio | 1.21 | 3.00 | 2.79 | 2.96 | 3.39 |
| Solvency Ratio | -1.38 | 0.92 | -0.45 | -1.04 | -0.64 |
| Operating Cash Flow Ratio | -2.11 | 1.62 | -1.34 | -2.45 | -1.61 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | € 7.49M | € 22.60M | € 9.51M | € 11.10M | € 30.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.07 | 0.07 | 0.07 | 0.05 |
| Debt-to-Equity Ratio | 0.14 | 0.10 | 0.09 | 0.10 | 0.06 |
| Debt-to-Capital Ratio | 0.12 | 0.09 | 0.08 | 0.09 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.51 | 1.40 | 1.33 | 1.41 | 1.33 |
| Debt Service Coverage Ratio | -25.85 | 21.52 | -17.01 | -51.41 | -38.09 |
| Interest Coverage Ratio | -29.47 | -13.24 | -27.43 | -54.52 | -44.80 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.27 | 0.34 | 0.34 | 0.23 | 0.22 |
| Net Debt to EBITDA | 0.39 | -1.41 | 2.83 | 1.16 | 1.73 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.77% | 93.65% | 87.00% | 85.23% | 96.40% |
| EBIT Margin | -265.89% | -27.89% | -94.80% | -319.75% | -183.11% |
| EBITDA Margin | -241.65% | 42.04% | -62.04% | -246.11% | -160.80% |
| Operating Profit Margin | -267.63% | -27.93% | -95.43% | -266.69% | -189.63% |
| Pretax Profit Margin | -274.98% | -30.00% | -98.28% | -324.64% | -187.34% |
| Net Profit Margin | -268.10% | -26.66% | -95.41% | -330.04% | -187.75% |
| Continuous Operations Profit Margin | -268.10% | -26.66% | -95.41% | -330.04% | -187.75% |
| Net Income Per EBT | 97.50% | 88.86% | 97.08% | 101.66% | 100.22% |
| EBT Per EBIT | 102.74% | 107.41% | 102.98% | 121.73% | 98.79% |
| Return on Assets (ROA) | -51.01% | -16.12% | -16.79% | -38.63% | -18.28% |
| Return on Equity (ROE) | -76.79% | -22.50% | -22.28% | -54.32% | -24.40% |
| Return on Capital Employed (ROCE) | -65.81% | -19.72% | -19.41% | -36.11% | -20.37% |
| Return on Invested Capital (ROIC) | -61.87% | -17.14% | -18.53% | -36.06% | -20.19% |
| Return on Tangible Assets | -73.99% | -19.87% | -34.01% | -66.97% | -27.15% |
| Earnings Yield | -41.83% | -16.64% | -14.14% | -17.68% | -10.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 14.50 | 9.64 | 10.07 | 10.09 | 22.67 |
| Payables Turnover | 4.83 | 3.13 | 2.73 | 2.98 | 0.28 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1292000.00 | 383000.00 |
| Fixed Asset Turnover | 1.76 | 7.11 | 2.13 | 1.27 | 1.20 |
| Asset Turnover | 0.19 | 0.60 | 0.18 | 0.12 | 0.10 |
| Working Capital Turnover Ratio | 0.30 | 1.36 | 0.00 | 0.25 | 0.21 |
| Cash Conversion Cycle | -50.37 | -78.85 | -97.41 | -86.16 | -1292.37 |
| Days of Sales Outstanding | 25.16 | 37.85 | 36.25 | 36.17 | 16.10 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 75.53 | 116.70 | 133.65 | 122.33 | 1308.47 |
| Operating Cycle | 25.16 | 37.85 | 36.25 | 36.17 | 16.10 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.17 | 0.93 | -0.83 | -1.01 | -0.67 |
| Free Cash Flow Per Share | -1.22 | 0.85 | -0.84 | -1.03 | -0.73 |
| Dividend Paid and CapEx Coverage Ratio | -22.77 | 11.89 | -86.03 | -51.21 | -11.50 |
| Capital Expenditure Coverage Ratio | -22.77 | 11.89 | -86.03 | -51.21 | -11.50 |
| Operating Cash Flow Coverage Ratio | -5.13 | 3.21 | -2.67 | -4.81 | -3.25 |
| Operating Cash Flow to Sales Ratio | -2.51 | 0.38 | -1.03 | -2.83 | -1.54 |
| Free Cash Flow Yield | -40.81% | 21.92% | -15.41% | -15.47% | -9.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.39 | -6.01 | -7.07 | -5.66 | -9.30 |
| Price-to-Sales (P/S) Ratio | 6.41 | 1.60 | 6.75 | 18.67 | 17.46 |
| Price-to-Book (P/B) Ratio | 1.84 | 1.35 | 1.58 | 3.07 | 2.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.45 | 4.56 | -6.49 | -6.46 | -10.40 |
| Price-to-Operating Cash Flow Ratio | -2.56 | 4.18 | -6.57 | -6.59 | -11.31 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.36 | 0.00 | -0.12 | -0.74 |
| Enterprise Value Multiple | -2.26 | 2.40 | -8.05 | -6.43 | -9.13 |
| Enterprise Value | 32.95M | 31.55M | 52.22M | 138.46M | 156.04M |
| EV to EBITDA | -2.26 | 2.40 | -8.05 | -6.43 | -9.13 |
| EV to Sales | 5.46 | 1.01 | 4.99 | 15.83 | 14.68 |
| EV to Free Cash Flow | -2.09 | 2.88 | -4.80 | -5.48 | -8.74 |
| EV to Operating Cash Flow | -2.18 | 2.63 | -4.86 | -5.59 | -9.50 |
| Tangible Book Value Per Share | 0.87 | 2.11 | 1.14 | 0.88 | 1.88 |
| Shareholders’ Equity Per Share | 1.63 | 2.86 | 3.47 | 2.16 | 3.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.11 | 0.03 | -0.02 | -0.00 |
| Revenue Per Share | 0.47 | 2.42 | 0.81 | 0.36 | 0.43 |
| Net Income Per Share | -1.25 | -0.64 | -0.77 | -1.18 | -0.81 |
| Tax Burden | 0.97 | 0.89 | 0.97 | 1.02 | 1.00 |
| Interest Burden | 1.03 | 1.08 | 1.04 | 1.02 | 1.02 |
| Research & Development to Revenue | 1.91 | 0.91 | 1.22 | 2.54 | 2.13 |
| SG&A to Revenue | 0.71 | 0.16 | 0.27 | 0.41 | 0.26 |
| Stock-Based Compensation to Revenue | 0.05 | 0.01 | 0.06 | 0.08 | 0.05 |
| Income Quality | 0.91 | -1.28 | 1.05 | 0.87 | 0.82 |
Currency in EUR

